Lymphoma, Malignant: Clinical Trials

9 trials for Lymphoma, Malignant, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 1 active not recruiting, 1 terminated, 1 unknown. 9 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 19Completed 5, Active not recruiting 1, Terminated 1, Unknown 1, Withdrawn 1
Phase 21Terminated 1

Follow Lymphoma, Malignant: new trials by email Literature Review of Lymphoma, Malignant trials Research Report on Lymphoma, Malignant

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor
TAK-659 - Lymphoma, Malignant, Advanced Solid Neoplasms
Phase 1WithdrawnCalithera Biosciences, Inc2018-02-282023-02-08
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
Fludarabine, Busulfan, Rabbit ATG - Leukemia, Lymphoid, Leukemia, Myeloid
Phase 1CompletedDartmouth-Hitchcock Medical Center202016-09-062023-10-18
DS-3201b in Participants With Lymphomas
DS-3201b - Lymphoma, Malignant, Non-hodgkin Lymphoma
Phase 1Active not recruitingDaiichi Sankyo Co., Ltd.1002016-03-312026-04-28
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
ASN002 Dose Escalation, ASN002 RD - Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell
Phase 1 / Phase 2TerminatedAsana BioSciences512015-05-012023-06-07
Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics
18F-Al-NOTA-PRGD2 PET/CT - Tumors, Carcinoma, Bronchogenic
Phase 1UnknownWuxi No. 4 People's Hospital2002012-01-012017-03-10
A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma
Enzastaurin - Solid Tumor, Lymphoma, Malignant
Phase 1CompletedEli Lilly and Company262011-11-012020-10-12
A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin
warfarin, enzastaurin - Solid Tumor, Lymphoma, Malignant
Phase 1CompletedEli Lilly and Company132011-08-012020-07-01
A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
SB1518 - Lymphoma, Malignant, Hodgkin's Lymphoma
Phase 1CompletedS*BIO352008-07-012012-04-20
Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma
E7820 - Neoplasms, Lymphoma, Malignant
Phase 1CompletedEisai Inc.372004-01-012014-12-23

Narrower conditions

Lymphoma (9)  ·  Lymphoma, B-Cell (3)  ·  Neoplasms (3)  ·  Lymphoma, Large B-Cell, Diffuse (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Lymphoma, T-Cell, Peripheral (2)  ·  Primary Myelofibrosis (2)  ·  Breast Neoplasms (1)  ·  Carcinoma, Bronchogenic (1)  ·  Head and Neck Neoplasms (1)  ·  Hodgkin Disease (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Leukemia, Lymphoid (1)  ·  Leukemia, Myeloid (1)  ·  Leukemia-Lymphoma, Adult T-Cell (1)

Broader conditions

Hemic and Lymphatic Diseases (9)  ·  Immune System Diseases (9)  ·  Immunoproliferative Disorders (9)  ·  Lymphatic Diseases (9)  ·  Lymphoproliferative Disorders (9)  ·  Neoplasms by Histologic Type (9)  ·  Neoplasms (6)  ·  Hematologic Diseases (3)  ·  Leukemia (3)  ·  Bone Marrow Diseases (2)  ·  Leukemia, Lymphoid (2)  ·  Lymphoma, T-Cell (2)  ·  Myeloproliferative Disorders (2)  ·  Blood Protein Disorders (1)  ·  Breast Diseases (1)

Interventions

enzastaurin (2)  ·  11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (1)  ·  Busulfan (1)  ·  Methotrexate (1)  ·  N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzene-sulfonamide (1)  ·  TAK-659 (1)  ·  Warfarin (1)  ·  fludarabine (1)  ·  thymoglobulin (1)

Sponsors

Eli Lilly and Company (2)  ·  Asana BioSciences (1)  ·  Calithera Biosciences, Inc (1)  ·  Daiichi Sankyo Co., Ltd. (1)  ·  Dartmouth-Hitchcock Medical Center (1)  ·  Eisai Inc. (1)  ·  S*BIO (1)  ·  Wuxi No. 4 People's Hospital (1)

Countries

United States (6)  ·  China (2)  ·  Argentina (1)  ·  France (1)  ·  Japan (1)

Top investigators

Anas Younes, M.D. (1)  ·  Jantien Wanders, M.D. (1)  ·  Kenneth Meehan, MD (1)  ·  Niranjan Rao, PhD (1)  ·  Weixing Wan, Professor (1)

Results publications

PMID 16818691, PMID 18077538, PMID 22965964, PMID 26942463, PMID 38967722, PMID 39486432, PMID 41150706, PMID 41258689